Which statement best describes the clinical use of measuring NT-proBNP?

Which statement best describes the clinical use of measuring NT-proBNP?

• A. Used to assess risk of coronary heart disease
• B. Used to assess risk of angina
• C. Used to assess individuals treated with nesiritide
• D. Used to assess individuals treated with vitamin B

Answer: (C)

NT-proBNP serves as a reliable marker of ventricular stress and heart failure status, and its interpretation is especially useful in patients who are receiving nesiritide. Nesiritide is a recombinant BNP, so measuring BNP levels can be confounded by the exogenous peptide, making BNP-based assessment unreliable in that setting. NT-proBNP, however, is a different peptide fragment not directly affected by nesiritide therapy, so its levels can still inform about cardiac status and prognosis when a patient is treated with nesiritide. In contrast, NT-proBNP is not primarily used to gauge coronary heart disease risk or angina risk, and it has no relevance to vitamin B treatment, which is why the statement about assessing individuals treated with nesiritide best describes its clinical use.

NT-proBNP serves as a reliable marker of ventricular stress and heart failure status, and its interpretation is especially useful in patients who are receiving nesiritide. Nesiritide is a recombinant BNP, so measuring BNP levels can be confounded by the exogenous peptide, making BNP-based assessment unreliable in that setting. NT-proBNP, however, is a different peptide fragment not directly affected by nesiritide therapy, so its levels can still inform about cardiac status and prognosis when a patient is treated with nesiritide. In contrast, NT-proBNP is not primarily used to gauge coronary heart disease risk or angina risk, and it has no relevance to vitamin B treatment, which is why the statement about assessing individuals treated with nesiritide best describes its clinical use.